BioNTech

BioNTech reported second-quarter revenue of EUR 106 million, or a 59% year-on-year decline. Management lowered its guidance for full-year revenue to EUR 1.6 billion-EUR 1.9 billion, or 19% lower than previous guidance at the midpoint, citing lower covid vaccine demand and delayed milestone payments.

Why it matters: Despite the downgrade in guidance, the pipeline remains on track, which is the more important component of BioNTech's story. Shares are up 1% from the previous day's close. On August 3, BioNTech announced the appointment of Guido Oelkers, Ph.D., as CEO. He has served as CEO of Swedish Orphan Biovitrum, or Sobi, since 2017 and will take office by Feb. 1, 2027, at the latest. This resolves the outstanding question of leadership succession after BioNTech's founders depart. Although Sobi is a rare-disease biopharma rather than an oncology firm like BioNTech, we think Dr. Oelkers' extensive experience overseeing late-stage pipeline development and commercialization will serve BioNTech well.

The bottom line: We maintain our fair value estimate for no-moat BioNTech of $76 per ADR. Given our Very High Uncertainty Rating, we currently view this stock as trading on the cusp of 3- and 4-star territory and think it has a lot of potential to rally or sell off depending on developing clinical trial data.

Coming up: In the second half of the year, we expect interim readouts for gotistobart (second-line squamous non-small cell lung cancer), BNT113 (HPV16-positive head and neck cancer), and T-pam (HR-positive HER2-low breast cancer).

We maintain our fair value estimate of $76 per ADR.

We project $4.2 billion of revenue in 10 years, which includes just under EUR 1 billion of covid vaccine revenue at the end of our 10-year forecast.

The most significant cancer antibody in development is pumitamig (PD-L1 and VEGF bispecific), which contributes about $1.8 billion of risk-adjusted revenue to our 2035 forecast. This pipeline asset potentially has broad applicability in many cancer indications where PD-(L)1 blockade has been successful and could be expanded to indications beyond.

We assume approximately EUR 1 billion of probability-adjusted contribution from its iNeST (personalized cancer vaccines) and FixVac (off-the-shelf cancer vaccines) programs by 2035.

We expect research and development costs to continue to ramp up as assets move into late-stage trials, although these costs will be mitigated by cost-sharing partnerships. We also assume selling, general, and administration costs continue to increase as drug candidates approach commercialization.

We assume an 8% cost of capital.

As an emerging biotechnology company, BioNTech does not, in our opinion, possess an economic moat. We think it has a strong but unproven portfolio of intangible assets in its pipeline, which is mostly in midstage development, and thus approval is highly uncertain.

Although Comirnaty, its only approved product, is a vaccine for an infectious disease, we view oncology as the company's primary focus. In the past, BioNTech was primarily focused on using its mRNA platform to treat cancer with cancer vaccines. However, since the covid pandemic, BioNTech has used the cash generated from Comirnaty to acquire other assets to augment its oncology pipeline with other modalities as well, including “mainstream” antibodies, antibody-drug conjugates, or ADCs, and bispecific antibodies. Its strategy is to secure near-term approvals for its late-stage pipeline candidates, mostly in smaller indications with lower approval hurdles, and later expand approvals to larger indications and test the modalities in combination to see if there are synergies.

The pipeline now has several assets entering late-stage development. These include: pumitamig, one of the two leading PD-L1 x VEGF bispecific candidates in global development; gotistobart, a CTLA antibody; BNT113, an off-the-shelf cancer vaccine for HPV-positive head and neck squamous cell carcinoma developed on BioNTech's fully-owned FixVac platform; antibody-drug conjugates T-pam (HER2-targeting), BNT324 (B7-H3-targeting), and BNT325 (TROP2-targeting), which were acquired from Chinese biotech Duality Bio; and BNT122, a personalized cancer vaccine in co-development with Roche on their iNeST platform.

We believe the development of individualized cancer immunotherapies on BioNTech and Roche's iNeST platform could be a moatworthy business if it succeeds in clinical trials. The personalized nature of this modality should command strong pricing power in the market. Despite higher costs to manufacture personalized medicine, we expect personalized cancer vaccines to be high-margin products as the business scales. Further, we expect this business will be difficult for competitors to replicate. The process leans heavily on bioinformatics, as researchers use proprietary programs to analyze a patient's DNA, identify the patient's unique mutations caused by the cancer, and determine which genetic instructions would produce an immune response sufficient to effectively attack the cancer cells. Then, researchers can engineer mRNA that encodes those unique mutations, producing that patient's personalized cancer vaccine. BioNTech's turnaround from start to delivery is between four and six weeks. Competitor Moderna is also developing personalized mRNA cancer vaccines and has similar production goals.

The most notable immuno-oncology antibody in development is pumitamig (formerly known as BNT327), a bispecific molecule targeting PD-L1 and VEGF, which is now undergoing phase 3 trials across various tumors. It was originally in-licensed from Biotheus, a Chinese biotech, in October 2023, and was acquired when BioNTech announced its $800 million purchase of Biotheus in November 2024. In June 2025, Bristol Myers Squibb agreed to pay BioNTech $3.5 billion in upfront and noncontingent payments and up to $7.6 billion in milestones to enter a 50/50 partnership. The most developed bispecific that targets the PD-(L)1 and VEGF pathways is ivonescimab, a competitor candidate that inhibits PD-1 and VEGF. Although pumitamig's development timeline is slightly behind ivonescimab's, given the large market potential of this bispecific strategy, we think there will be room for pumitamig to compete if both drugs are ultimately approved. We think pumitamig could receive its first approval around 2029-2030, with small-cell lung cancer as its first indication.

Overall, we think the company has several promising candidates that could one day support a moat, but they are too early in the development process to warrant a narrow moat. We currently give the company's clinical drug candidates probabilities of approval between 10% and 60%, with most of these therapies potentially reaching the market in the 2027-30 time frame.

BioNTech owns a diverse portfolio of modalities for oncology, including bispecific antibodies, antibody-drug conjugates, and mRNA cancer vaccines, which gives it freedom to explore these in combination for possible synergies.

BioNTech should be able to command a premium price for its personalized mRNA cancer therapies, if successful.

BioNTech is co-developing pumitamig with Bristol Myers Squibb, and it is one of the lead PD-(L)1 x VEGF bispecific antibodies with large commercial potential.

BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.

Depending on the pandemic's evolution, the company may not be consistently profitable for several more years, potentially burning the cash from 2021-22 covid vaccine sales as it develops several assets simultaneously.

The competitive landscape in oncology is intense and risky, with several other entrenched firms vying to innovative and improve their offerings as BioNTech seeks to launch its first drugs.